Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

5.550 +0.110 (+2.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 4 Next >
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance Halozyme's revenue growth and portfolio. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the company. 
Via Benzinga
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Insights into Evotec's Upcoming Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Is Evotec Stock Gaining Today?
Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment. 
Via Benzinga
Sherwin-Williams, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
Evotec and Novo Nordisk have partnered to develop off-the-shelf cell therapy products. The collaboration will focus on advancing stem cell-based therapies for potential commercialization. 
Via Benzinga
FedEx Reports Downbeat Results, Joins MillerKnoll And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction. 
Via Benzinga
Topics Workforce
Exposures Layoff
EVO Stock Earnings: Evotec Misses EPS, Misses Revenue for Q2 2024
EVO stock results show that Evotec missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
EVO Stock Earnings: Evotec Beats EPS, Beats Revenue for Q1 2024
EVO stock results show that Evotec beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Growth Stocks to Buy at 52-Week Lows
Looking for some compelling bargains? It's time to add these three growth stocks at 52-week lows to your watchlist. 
Via InvestorPlace
Crude Oil Moves Lower; B. Riley Financial Shares Jump
Via Benzinga
Exposures Fossil Fuels
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Rises 0.5%; Tesla Shares Jump After Q1 Results
Via Benzinga
Life Science-Focused Evotec Shares Plunge To 6 Year Lows On Gloomy Annual Forecast
Evotec undergoes a strategic shift for sustainable growth in 2024. Priority reset to optimize operations; expect double-digit revenue growth & EBITDA improvement. New CEO appointed. Guidance and... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.